March 30th, 2022
9AM-11AM ET
The virtual R&D Day will highlight Immunovant’s vision to enable normal lives for people with autoimmune diseases and provide insights into the broad potential of batoclimab, a novel, fully human monoclonal antibody designed to selectively bind to and inhibit the neonatal Fc receptor (FcRn), thus blocking the recycling of IgG antibodies. This event will feature six key opinion leaders with expertise in thyroid eye disease, myasthenia gravis, warm autoimmune hemolytic anemia, and cholesterol management.
A live question and answer session with Immunovant management will follow.